Canterbury DHB



This refers to the infusion of blood or recombinant products in anticipation of or in order to prevent bleeding. This contrasts with on-demand therapy given at the first sign of a bleed.

Prophylaxis may be:

Who should receive prophylaxis?

Primary prophylaxis is standard treatment for infants with severe haemophilia (<1% factor) who declare themselves at high risk for the development of haemophiliac arthropathy.

When should treatment start?

In general, treatment is commenced within the first 12 to 24 months of life. It is normally commenced following the first significant spontaneous bleed (joint or soft tissue). A Port-a-Cath device may be needed to facilitate vascular access.

Short-term prophylaxis may be required for a patient with recurrent bleeding into a target joint.

In This Section

Haemophilia A

Haemophilia B

About this Canterbury DHB document (5236):

Document Owner:

Sean Macpherson (see Who's Who)

Last Reviewed:

November 2019

Next Review:

November 2022


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5236